Therapix Biosciences Provides Portfolio Update

TEL AVIV, Israel, January 11, 2017 /PRNewswire/ --

Therapix Biosciences  (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based drugs, reported that in its ongoing product portfolio review in order to maximize the potential value of product development, it has determined to advance one additional development program and to extend its Mild Cognitive Impairment (MCI) program.  

The additional program is in the area of antibiotic therapies, an area which we believe is in need of improved products.  The company's objective is to use its "entourage effect" technology to enhance the efficacy of existing antibiotic drugs especially in antibiotic resistant conditions. Therapix's "entourage effect" technology combines cannabinoids with the company's proprietary endocannabinoid to enhance the effect of the cannabinoids while potentially improving the side-effect profile.

The second indication is an extension of the company's current program using its proprietary ultra-low dose cannabinoid technology in MCI and will advance a development program on the treatment of cognitive impairment in sports-related brain injuries.

These product development programs are in line with the company's business strategy to create and expand a portfolio of cannabinoid-based treatments.  

Therapix recently initiated a clinical proof-of-concept trial for the Company's THX-TS01 which is in development for the treatment of Tourette's syndrome.

About Therapix  

Therapix is an Israeli-based clinical-stage pharma company focused on the development and commercialization of cannabinoid drugs.  The company is listed on the Tel Aviv Stock Exchange and traded over-the counter (OTC) in the United States. Therapix's CEO is Dr. Elran Haber and its Chairman is Dr. Ascher Shmulewitz.

Forward Looking Statements  

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the company's plans with respect to its clinical trials and drug development programs. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Therapix Biosciences Ltd.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

For further details, Goldfinger Communications, Irit Yosilevitch, +972-052-3887799 

SOURCE Therapix Biosciences